Targeting Schizophrenia: A Review of Pharmacological and Psychosocial Innovations
DOI:
https://doi.org/10.12775/QS.2026.49.67583Keywords
schizophrenia, antipsychotics, dopamine, treatment, CBT, cariprazine, symptoms in schizophrenia, dopamine receptorsAbstract
Background. Paranoid schizophrenia is the most common subtype of schizophrenia, characterized by both positive symptoms, such as hallucinations and delusions, and negative symptoms like reduced motivation and social withdrawal. While pharmacological advances have improved symptom control, challenges remain in treating negative symptoms and ensuring long-term adherence and recovery.
Aim of the study. This review analyzes recent literature (2020–2025) on pharmacological and psychosocial treatment strategies for paranoid schizophrenia, with attention to effectiveness, tolerability, and integration.
Materials and methods. PubMed and Google Scholar were searched for meta-analyses, RCTs, and guidelines published in the last 5 years using terms like “paranoid schizophrenia”, “antipsychotics”, “long-acting injectables”, “CBT”, “treatment”.
Current stage of knowledge. Modern antipsychotics, particularly SGAs and LAIs, reduce relapse risk and enhance adherence. Cariprazine and newer agents like Cobenfy show promise in treating negative and treatment-resistant cases. Integration with psychosocial strategies—especially CBT and family interventions—enhances functional recovery, though results for negative symptoms remain mixed. Novel treatments target glutamatergic and cholinergic systems beyond traditional dopaminergic focus.
Conclusions. A multimodal approach is essential. Future treatment should emphasize personalized strategies, early intervention, targeting of non-dopaminergic pathways, and better access to integrated care, particularly for patients with persistent negative or cognitive symptoms.
References
Faden, J., & Citrome, L. (2023). Schizophrenia: One Name, Many Different Manifestations. Medical Clinics of North America, 107(1), 61–72. https://doi.org/10.1016/j.mcna.2022.05.005
Valle, R. (2020). Schizophrenia in ICD-11: Comparison of ICD-10 and DSM-5. Revista de Psiquiatria y Salud Mental, 13(2), 95–104. https://doi.org/10.1016/j.rpsm.2020.01.001
Crawford, P., & Go, K. v. (2022). Schizophrenia. American Family Physician, 106(4), 388–396.
Takeda, T., Umehara, H., Matsumoto, Y., Yoshida, T., Nakataki, M., & Numata, S. (2024). Schizophrenia and cognitive dysfunction. The Journal of Medical Investigation : JMI, 71(3.4), 205–209. https://doi.org/10.2152/jmi.71.205
Japanese Society of Neuropsychopharmacology, & Japanese Society of Clinical Neuropsychopharmacology. (2025). Guideline for pharmacological treatment of schizophrenia 2022. Neuropsychopharmacology Reports, 45(1), e12497. https://doi.org/10.1002/npr2.12497
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. The Lancet Psychiatry, 8(5), 387–404. https://doi.org/10.1016/S2215-0366(21)00039-0
Wang, D., Schneider-Thoma, J., Siafis, S., Burschinski, A., Dong, S., Wu, H., Zhu, Y., Davis, J. M., Priller, J., & Leucht, S. (2024). Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials. Schizophrenia Bulletin, 50(1), 132–144. https://doi.org/10.1093/schbul/sbad089
Berendsen, S., Berendse, S., van der Torren, J., Vermeulen, J., & de Haan, L. (2024). Cognitive behavioural therapy for the treatment of schizophrenia spectrum disorders: an umbrella review of meta-analyses of randomised controlled trials. EClinicalMedicine, 67, 102392. https://doi.org/10.1016/j.eclinm.2023.102392
Woolway, G. E., Smart, S. E., Lynham, A. J., Lloyd, J. L., Owen, M. J., Jones, I. R., Walters, J. T. R., & Legge, S. E. (2022). Schizophrenia Polygenic Risk and Experiences of Childhood Adversity: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 48(5), 967–980. https://doi.org/10.1093/schbul/sbac049
McCutcheon, R. A., Abi-Dargham, A., & Howes, O. D. (2019). Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms. Trends in Neurosciences, 42(3), 205–220. https://doi.org/10.1016/j.tins.2018.12.004
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023). Dopamine, Immunity, and Disease. Pharmacological Reviews, 75(1), 62–158. https://doi.org/10.1124/pharmrev.122.000618
Keshavan, M. S., & Song, S. H. (2024). Neuroscience in Pictures: 3. Schizophrenia. Asian Journal of Psychiatry, 102, 104278. https://doi.org/10.1016/j.ajp.2024.104278
Howes, O. D., & Shatalina, E. (2022). Integrating the Neurodevelopmental and Dopamine Hypotheses of Schizophrenia and the Role of Cortical Excitation-Inhibition Balance. Biological Psychiatry, 92(6), 501–513. https://doi.org/10.1016/j.biopsych.2022.06.017
Kesby, J., Eyles, D., McGrath, J., & Scott, J. (2018). Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Translational Psychiatry, 8(1), 30. https://doi.org/10.1038/s41398-017-0071-9
Marder, S. R., & Umbricht, D. (2023). Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments. Schizophrenia Research, 258, 71–77. https://doi.org/10.1016/j.schres.2023.07.010
Kinon, B. J., Leucht, S., Tamminga, C., Breier, A., Marcus, R., & Paul, S. M. (2024). Rationale for Adjunctive Treatment Targeting Multiple Mechanisms in Schizophrenia. The Journal of Clinical Psychiatry, 85(3). https://doi.org/10.4088/JCP.23nr15240
Elsheikh, S. S. M., Müller, D. J., & Pouget, J. G. (2022). Pharmacogenetics of Antipsychotic Treatment in Schizophrenia(pp. 389–425). https://doi.org/10.1007/978-1-0716-2573-6_14
Orzelska-Górka, J., Mikulska, J., Wiszniewska, A., & Biała, G. (2022). New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression. International Journal of Molecular Sciences, 23(18), 10624. https://doi.org/10.3390/ijms231810624
Lian, L., Kim, D. D., Procyshyn, R. M., Cázares, D., Honer, W. G., & Barr, A. M. (2022). Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLOS ONE, 17(4), e0267808. https://doi.org/10.1371/journal.pone.0267808
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider-Thoma, J., Davis, J. M., & Leucht, S. (2023). Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis. Molecular Psychiatry, 28(8), 3267–3277. https://doi.org/10.1038/s41380-023-02203-y
Schoretsanitis, G., Meyer, J. M., Conca, A., & Hiemke, C. (2023). Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations. Expert Opinion on Drug Metabolism & Toxicology, 19(4), 189–202. https://doi.org/10.1080/17425255.2023.2220962
Torres-Carmona, E., Nakajima, S., Iwata, Y., Ueno, F., Stefan, C., Song, J., Abdolizadeh, A., Koizumi, M. T., Kambari, Y., Amaev, A., Agarwal, S. M., Mar, W., de Luca, V., Remington, G., Gerretsen, P., & Graff-Guerrero, A. (2024). Clozapine treatment and astrocyte activity in treatment resistant schizophrenia: A proton magnetic resonance spectroscopy study. Schizophrenia Research, 270, 152–161. https://doi.org/10.1016/j.schres.2024.06.020
Rognoni, C., Bertolani, A., & Jommi, C. (2021). Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects. Clinical Drug Investigation, 41(4), 303–319. https://doi.org/10.1007/s40261-021-01000-1
Koziej, S., Kowalczyk, E., & Soroka, E. (2024). Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 30, e945411. https://doi.org/10.12659/MSM.945411
Hasan, A. H., & Abid, M. A. (2024). Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. Cureus, 16(10), e71131. https://doi.org/10.7759/cureus.71131
Starzer, M. K., Nordholm, D., Hansen, H. G., & Nordentoft, M. (2022). [Non-pharmacological therapies show effect in the treatment of schizophrenia]. Ugeskrift for Laeger, 184(28).
Correll, C. U., Kim, E., Sliwa, J. K., Hamm, W., Gopal, S., Mathews, M., Venkatasubramanian, R., & Saklad, S. R. (2021). Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs, 35(1), 39–59. https://doi.org/10.1007/s40263-020-00779-5
Samochowiec, J., Szulc, A., Bieńkowski, P., Dudek, D., Gałecki, P., Heitzman, J., Wojnar, M., & Wichniak, A. (2021). Polish Psychiatric Association consensus statement on non-pharmacological methods in the treatment of negative symptoms of schizophrenia. Psychiatria Polska, 55(4), 719–742. https://doi.org/10.12740/PP/OnlineFirst/135527
Guaiana, G., Abbatecola, M., Aali, G., Tarantino, F., Ebuenyi, I. D., Lucarini, V., Li, W., Zhang, C., & Pinto, A. (2022). Cognitive behavioural therapy (group) for schizophrenia. The Cochrane Database of Systematic Reviews, 7(7), CD009608. https://doi.org/10.1002/14651858.CD009608.pub2
Xu, F., & Xu, S. (2024). Cognitive-behavioral therapy for negative symptoms of schizophrenia: A systematic review and meta-analysis. Medicine, 103(36), e39572. https://doi.org/10.1097/MD.0000000000039572
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Urszula Janicka, Klaudia Bogdan, Mikołaj Jankowski, Natalia Ciepluch, Szymon Słomiński, Wiktoria Toczek, Magdalena Olszówka, Sonia Dziugieł
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 104
Number of citations: 0
